巴瑞替尼对难治性类风湿关节炎既往生物制剂使用情况的疗效反应
RA-BEACON研究的事后亚组分析评估了巴瑞替尼对一种或多种TNF抑制剂应答不足的类风湿关节炎患者的疗效,重点关注基线特征和既往生物制剂暴露的影响。结果发现巴瑞替尼的疗效总体优于安慰剂,且在不同既往生物制剂使用亚组中表现一致;但既往生物制剂使用越多,治疗中出现的不良事件(包括感染)发生率似有升高。
要点
- 巴瑞替尼4 mg在既往生物制剂难治的类风湿关节炎患者中,ACR20第12周和第24周的比值比分别为3.4和2.4,总体优于安慰剂。
- 按地区分层的ACR20和按病程分层的CDAI≤10存在显著定量交互作用,欧洲地区效应更大,病程≥10年效应更大。
- 既往生物制剂使用越多,各组治疗中出现的不良事件(包括感染)发生率似有升高。
核心结论
- 巴瑞替尼在既往生物制剂难治的类风湿关节炎患者中,基于基线特征和既往生物制剂使用的各亚组均显示出持续一致的有益治疗效果。
研究设计与样本
- RA-BEACON研究为随机对照试验,患者按1:1:1随机分配至每日一次安慰剂或巴瑞替尼2 mg或4 mg,允许既往使用生物制剂。
- 本分析为探索性、主要为事后亚组分析,评估第12周和第24周的ACR20和CDAI≤10应答。
主要发现
- 巴瑞替尼4 mg vs 安慰剂第12周ACR20的比值比为3.4,第24周ACR20的比值比为2.4。
- 巴瑞替尼4 mg vs 安慰剂第12周和第24周按地区分层的ACR20存在显著定量交互作用,欧洲地区效应更大。
- 巴瑞替尼4 mg vs 安慰剂第12周和第24周按病程分层的CDAI≤10存在显著定量交互作用,病程≥10年效应更大。
- 按年龄、体重、病程、血清阳性、糖皮质激素使用、既往生物制剂数量、TNF抑制剂或非TNF抑制剂数量或特定既往TNF抑制剂分层的ACR20未持续观察到显著交互作用。
- 既往生物制剂使用越多,各组治疗中出现的不良事件(包括感染)发生率似有升高。
关键数值与推荐
- 交互作用P值≤0.10被认为显著,第12周和第24周均显著赋予更大权重。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet medical need. We evaluated the effects of baseline characteristics, including prior bDMARD exposure, on baricitinib efficacy and safety. METHODS: RA-BEACON patients (previously reported) had moderate to severe RA with insufficient response to one or more TNF inhibitor and were randomized 1:1:1 to once-daily placebo or 2 or 4 mg baricitinib. Prior bDMARD use was allowed. The primary endpoint was a 20% improvement in ACR criteria (ACR20) at week 12 for 4 mg vs placebo. An exploratory, primarily post hoc, subgroup analysis evaluated efficacy at weeks 12 and 24 by ACR20 and Clinical Disease Activity Index (CDAI) ⩽10. An interaction P-value ⩽0.10 was considered significant, with significance at both weeks 12 and 24 given more weight. RESULTS: The odds ratios predominantly favored baricitinib over placebo and were generally similar to those in the overall study (3.4, 2.4 for ACR20 weeks 12 and 24, respectively). Significant quantitative interactions were observed for baricitinib 4 mg vs placebo at weeks 12 and 24: ACR20 by region (larger effect Europe) and CDAI ⩽10 by disease duration (larger effect ⩾10 years). No significant interactions were consistently observed for ACR20 by age; weight; disease duration; seropositivity; corticosteroid use; number of prior bDMARDs, TNF inhibitors or non-TNF inhibitors; or a specific prior TNF inhibitor. Treatment-emergent adverse event rates, including infections, appeared somewhat higher across groups with greater prior bDMARD use. CONCLUSION: Baricitinib demonstrated a consistent, beneficial treatment effect in bDMARD-refractory patients across subgroups based on baseline characteristics and prior bDMARD use. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov/), NCT01721044.
引用
- Genovese MC, Kremer JM, Kartman CE, et al. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology (Oxford). 2018. PMID: 29415145. doi:10.1093/rheumatology/kex489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。